Cancer Research and Treatment

Original Articles

General

Development and Feasibility Evaluation of Smart Cancer Care 2.0 Based on Patient-Reported Outcomes for Post-Discharge Management of Patients with Cancer: Jin Ah Kwon, Songsoo Yang, Su-Jin Koh, Young Ju Noh, Dong Yoon Kang, Sol Bin Yang, Eun Ji Kwon, Jeong-Wook Seo, Jin sung Kim, Minsu Ock; Cancer Res Treat. 2024;56(4):1040-1049. Published online April 9, 2024; DOI: https://doi.org/10.4143/crt.2024.003

Abstract PDF Supplementary Material PubReader ePub: Purpose
A “Smart Cancer Care” platform that integrates patient-reported outcomes (PROs) with management has been established in Korea. This study focused on improving health behaviors and connecting patients to welfare services by introducing and assessing the feasibility of “Smart Cancer Care 2.0,” an enhanced version designed for monitoring complications post-cancer treatment.
Materials and Methods
Smart Cancer Care 2.0 was developed by conducting a literature review and consulting with expert panels to identify symptoms or variables requiring monitoring and management guidelines based on the treatment type. Qualitative and quantitative surveys were conducted to assess the feasibility of the app and web system based on the experiences of patients with cancer and healthcare workers.
Results
A total of 81 symptoms or variables (chemotherapy-, surgery-, radiotherapy-, rehabilitation-, and health management-related) were selected for management in Smart Cancer Care 2.0. PROs for these symptoms were basically categorized into three severity grades: preventive management, self-treatment, and consultation with a healthcare worker or visit to a healthcare institution. The overall mean scores in the feasibility evaluation by patients and healthcare workers were 3.83 and 3.90 points, respectively, indicating high usefulness.
Conclusion
Smart Cancer Care 2.0 leverages the existing information and communication technologies–based platform, Smart Cancer Care, and further includes health behaviors and welfare services. Smart Cancer Care 2.0 may play a crucial role in establishing a comprehensive post-discharge management system for patients with cancer as it provides suitable interventions based on patients’ responses and allows the regularly collected PROs to be easily viewed for streamlined care.

1,503 View
100 Download

Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy: Erta Kalanxhi, Karianne Risberg, Imon S. Barua, Svein Dueland, Stein Waagene, Solveig Norheim Andersen, Solveig J. Pettersen, Jessica M. Lindvall, Kathrine Røe Redalen, Kjersti Flatmark, Anne Hansen Ree; Cancer Res Treat. 2017;49(2):374-386. Published online July 28, 2016; DOI: https://doi.org/10.4143/crt.2016.080

Abstract PDF PubReader ePub

Purpose
When integrating molecularly targeted compounds in radiotherapy, synergistic effects of the systemic agent and radiation may extend the limits of patient tolerance, increasing the demand for understanding the pathophysiological mechanisms of treatment toxicity. In this Pelvic Radiation and Vorinostat (PRAVO) study, we investigated mechanisms of adverse effects in response to the histone deacetylase (HDAC) inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) when administered as a potential radiosensitiser.
Materials and Methods
This phase I study for advanced gastrointestinal carcinoma was conducted in sequential patient cohorts exposed to escalating doses of vorinostat combined with standard-fractionated palliative radiotherapy to pelvic target volumes. Gene expression microarray analysis of the study patient peripheral blood mononuclear cells (PBMC) was followed by functional validation in cultured cell lines and mice treated with SAHA.
Results
PBMC transcriptional responses to vorinostat, including induction of apoptosis, were confined to the patient cohort reporting dose-limiting intestinal toxicities. At relevant SAHA concentrations, apoptotic features (annexin V staining and caspase 3/7 activation, but not poly-(ADP-ribose)-polymerase cleavage) were observed in cultured intestinal epithelial cells. Moreover, SAHA-treated mice displayed significant weight loss.
Conclusion
The PRAVO study design implemented a strategy to explore treatment toxicity caused by an HDAC inhibitor when combined with radiotherapy and enabled the identification of apoptosis as a potential mechanism responsible for the dose-limiting effects of vorinostat. To the best of our knowledge, this is the first report deciphering mechanisms of normal tissue adverse effects in response to an HDAC inhibitor within a combined-modality treatment regimen.

Citations

Citations to this article as recorded by

Effect of MicroRNA-210 on the Growth of Ovarian Cancer Cells and the Efficacy of Radiotherapy
Yinlong Zhao, Shirui Liu, Yu Wen, Lili Zhong
Gynecologic and Obstetric Investigation.2021; 86(1-2): 71. CrossRef
Valproic Acid Downregulates Cytokine Expression in Human Macrophages Infected with Dengue Virus
Félix G. Delgado, Paola Cárdenas, Jaime E. Castellanos
Diseases.2018; 6(3): 59. CrossRef
Synthesis, cytotoxic activity, and mode of action of new Santacruzamate A analogs
Silmara N. Andrade, Fernanda C. G. Evangelista, Diego Seckler, Deisielly R. Marques, Túlio R. Freitas, Renata R. Nunes, Júlia T. Oliveira, Rosy I. M. A. Ribeiro, Hélio B. Santos, Ralph G. Thomé, Alex G. Taranto, Fabio V. Santos, Gustavo H. R. Viana, Rossi
Medicinal Chemistry Research.2018; 27(11-12): 2397. CrossRef
Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity
Blaz Groselj, Jia-Ling Ruan, Helen Scott, Jessica Gorrill, Judith Nicholson, Jacqueline Kelly, Selvakumar Anbalagan, James Thompson, Michael R.L. Stratford, Sarah J. Jevons, Ester M. Hammond, Cheryl L. Scudamore, Martin Kerr, Anne E. Kiltie
Molecular Cancer Therapeutics.2018; 17(2): 381. CrossRef

14,984 View
212 Download
4 Web of Science
4 Crossref

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients: Seung-Hoon Beom, Dong-Wan Kim, Sung Hoon Sim, Bhumsuk Keam, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo; Cancer Res Treat. 2016;48(1):88-97. Published online March 3, 2015; DOI: https://doi.org/10.4143/crt.2014.201

Abstract PDF PubReader ePub

Purpose
Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the incidence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carcinoma patients treated with gefitinib. Materials and Methods A retrospective cohort study was performed in non-small cell lung cancer (NSCLC) patients who started gefitinib treatment at Seoul National University Hospital from January 2002 through December 2011. Patients who developed new abnormal radiologic findings with respiratory symptoms after gefitinib treatment were defined as having possible adverse pulmonary reactions. The patients’ medical records were reviewed independently by investigators to identify the causes of pulmonary toxicities. Results Among the 1,114 patients evaluated, 128 patients (11.5%) developed pulmonary adverse reactions after taking gefitinib. An infectious complication occurred in 98 patients (8.8%) and 15 patients (1.3%) developed ILD. Nine of the 15 patients (60.0%) with gefitinib-induced ILD experienced a fatal clinical course that met either the Common Terminology Criteria for Adverse Events grade 4 (n=3) or grade 5 (n=6). In the multivariate analysis, a lower serum albumin level (≤ 3.0 g/dL) at baseline was significantly associated with the development of gefitinib-induced ILD (odds ratio, 3.91; 95% confidence interval, 1.20 to 12.71). Conclusion The incidence of gefitinib-induced ILD in Korean NSCLC patients was similar to that reported worldwide, but lower than values reported for Japanese population. ILD was usually a lifethreatening adverse effect of gefitinib, and the development of ILD was significantly associated with a lower baseline serum albumin level.

Citations

Citations to this article as recorded by

Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis
Yosuke Fukuda, Yoshitaka Uchida, Koichi Ando, Ryo Manabe, Akihiko Tanaka, Hironori Sagara
Respiratory Investigation.2024; 62(3): 481. CrossRef
Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats
Wael A. Alanazi, Hussain N. Alhamami, Ali A. Alshamrani, Faleh Alqahtani, Abdulrahman Alshammari, Khalid Alhazzani, Mohammed Alswayyed
Saudi Journal of Biological Sciences.2023; 30(2): 103522. CrossRef
Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan
Qingqing Hu, Kuan-Chih Huang, Choo Hua Goh, Yumi Tsuchiya, Yanfang Liu, Hong Qiu
Scientific Reports.2023;[Epub] CrossRef
Sensorineural hearing loss induced by gefitinib: A CARE-compliant case report and literature reviews
Bao-chen Zhu, Wen-hua Yang, Mao Huang, Jin-gui Wang, Yan Liang, Zhen-zhen Lei, Sha-sha Zhang, Ying Wang, Xiao-di Sun, Ying Gong, Chun-miao Xue, Guo-dong Hua
Medicine.2023; 102(45): e36010. CrossRef
Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism
Alessio Basolo, Antonio Matrone, Rossella Elisei, Ferruccio Santini
Seminars in Cancer Biology.2022; 79: 197. CrossRef
Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience
Min-Young Lee, Seug Yun Yoon, Kyoung Ha Kim, Namsu Lee, Ha Youn Kim, Jung Hwa Hwang, Jong-Ho Won
The Korean Journal of Internal Medicine.2021; 36(3): 689. CrossRef
Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China
Xie Xiaohong, Wang Liqiang, Li Na, Lin Xinqing, Qin Yinyin, Liu Ming, Ouyang Ming, Han Qian, Luo Qun, Li Shiyue, Li Chunyan, Wang Xiaoqian, Yang Shuanying, Huang Wei, Liu Mei, Wang Ping, Zhou Chengzhi
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis
Tomonori Hirashima, Miyako Satouchi, Toyoaki Hida, Makoto Nishio, Terufumi Kato, Hiroshi Sakai, Fumio Imamura, Katsuyuki Kiura, Isamu Okamoto, Kazuo Kasahara, Hirohiko Uchida, Sarah L. Vowler, Tetsuya Mitsudomi
Cancer Science.2019; 110(9): 2884. CrossRef
Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective
Shigeki Saito, Joseph A. Lasky, Koichi Hagiwara, Yasuhiro Kondoh
Respiratory Investigation.2018; 56(5): 375. CrossRef
Personalized chemotherapy of lung cancer: What the radiologist should know
G.R. Ferretti, E. Reymond, A. Delouche, L. Sakhri, A. Jankowski, D. Moro-Sibilot, S. Lantuejoul, A.C. Toffart
Diagnostic and Interventional Imaging.2016; 97(3): 287. CrossRef
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
Rashmi R. Shah
Drug Safety.2016; 39(11): 1073. CrossRef
Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer
Namhun Lee, Kangwook Lee, Yoon-sik Kim, Chang-Gue Son, Jung-Hyo Cho, Hwa-Seung Yoo, Jonghoon Lee, Juyoung Ryu
Journal of Pharmacopuncture.2016; 19(3): 259. CrossRef
Imagerie du suivi post-thérapeutique des traitements personnalisés systémiques du cancer bronchique
G. Ferretti, E. Reymond, J. Cohen, A. Jankowski, M. Giaj-Levra, A.C. Toffart, D. Moro-Sibilot
Revue des Maladies Respiratoires Actualités.2016; 8(5): 325. CrossRef

14,807 View
132 Download
14 Web of Science
13 Crossref

First
Prev
Page of 1
Next
Last

Search